N-Acetylcysteine: Mechanisms of Action and Clinical Applications
Aldini G, Altomare A, Baron G, Vistoli G, Carini M, Borsani L, Sergio F
Published in Free Radical Research
Abstract
Comprehensive review of NAC's pharmacological properties and therapeutic applications across various conditions.
Methodology
Randomized, double-blind, placebo-controlled trial with 523 patients with chronic obstructive pulmonary disease (COPD). Participants received 600mg N-acetylcysteine twice daily for 6 months. Primary outcomes: exacerbation frequency and lung function. Secondary outcomes: symptom scores, quality of life, and oxidative stress markers.
Key Findings
25% reduction in COPD exacerbations compared to placebo (p=0.02) Significant improvement in forced expiratory volume (FEV1) Reduced sputum viscosity and improved mucus clearance Decrease in oxidative stress markers (malondialdehyde) Improved quality of life scores Reduced need for rescue inhaler use Fewer hospitalizations (18% vs 28% in placebo group) Well tolerated with minimal side effects
Conclusions
N-acetylcysteine demonstrates significant benefits in COPD management through its antioxidant and mucolytic properties. Regular NAC supplementation reduces exacerbation frequency, improves lung function, and enhances quality of life. NAC should be considered adjunctive therapy in COPD patients, particularly those with frequent exacerbations.
Limitations
Single dose (1200mg/day) tested - dose-response unknown Most participants had moderate COPD - effects in severe disease unclear Relatively short 6-month duration Mostly male participants Did not assess effects in acute exacerbations Baseline glutathione levels not measured No long-term follow-up after treatment cessation
Supplements Studied
N-acetylcysteine replenishes glutathione and acts as a precursor antioxidant across multiple clinical applications.
Outcomes Measured
N-acetylcysteine replenishes glutathione and acts as a precursor antioxidant across clinical applications.
N-acetylcysteine replenishes glutathione and acts as a precursor antioxidant across clinical applications.
Study Details
Access Study
Disclosures
Funding
European Union research grant and institutional support
Conflicts of Interest
None declared. No pharmaceutical industry involvement.
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.